FrancophonIA/ELRC3.0 huggingface dataset:
English: - The other ingredients are mannitol (E421) and nitrogen.
Danish: - Øvrige indholdsstoffer: Mannitol (E421) og nitrogen.
English: The analysis demonstrated improved ORR (CR+PR) (odds ratio 3.769; 95% CI 2.045-6.947; p < 0.001), PFS (hazard ratio 0.511; 95% CI 0.309-0.845; p=0.008), TTP (hazard ratio 0.385; 95% CI 0.212-0.698; p=0.001) for VELCADE in combination with dexamethasone over VELCADE monotherapy.
Danish: Analysen påviste forbedret ORR (CR+PR) (odds-ratio 3,769; 95 % CI 2,045-6,947; p < 0,001), PFS (hazard ratio 0,511; 95 % CI 0,309--0,845; p = 0,008), TTP (hazard ratio 0,385; 95 % CI 0,212--0,698; p = 0,001) for VELCADE sammen med dexamethason over VELCADE som monoterapi.
English: Overall response (CR+CRu+PR)
Danish: Samlet respons (CR+CRu+PR)
English: Gastrointestinal toxicity, including nausea, diarrhoea, vomiting and constipation are very common with VELCADE treatment.
Danish: Gastrointestinal toksicitet, inklusive kvalme, diaré, opkastning og forstoppelse, er meget almindelig ved behandling med VELCADE.
English: It is recommended that patients receive 2 cycles of VELCADE following a confirmation of a complete response.
Danish: Det anbefales, at patienterne får to cyklusser med VELCADE efter bekræftelse af et komplet respons.
English: Since dialysis may reduce bortezomib concentrations, VELCADE should be administered after the dialysis procedure (see section 5.2).
Danish: Da dialyse kan reducere koncentrationen af bortezomib, bør VELCADE gives efter dialyse (se pkt.
English: • Weight increase
Danish: • Vægtstigning
English: In the Phase III study, treatment with VELCADE led to a significantly longer time to progression, a significantly prolonged survival and a significantly higher response rate, compared to treatment with dexamethasone (see Table 14), in all patients as well as in patients who have received 1 prior line of therapy.
Danish: I fase III-studiet førte behandlingen med VELCADE til signifikant længere tid indtil progression, en signifikant længere overlevelse og en signifikant højere responsrate sammenlignet med behandling med dexamethason (se tabel 14) hos alle patienter samt hos patienter, som tidligere havde fået én behandling.
English: The overall best response rate (CR + PR), to retreatment in 130 patients was 38.5% (95% CI: 30.1, 47.4).
Danish: Den samlede bedste responsrate (CR + PR) ved genbehandling af 130 patienter var 38,5 % (95 % CI: 30,1-47,4).
English: The European Medicines Agency has waived the obligation to submit the results of studies with VELCADE in all subsets of the paediatric population in multiple myeloma and in mantle cell lymphoma (see section 4.2 for information on paediatric use).
Danish: Det Europæiske Lægemiddelagentur har dispenseret fra kravet om at fremlægge resultaterne af studier med VELCADE i alle undergrupper af den pædiatriske population ved myelomatose og ved mantlecelle-lymfom (se pkt.
English: The following adverse reactions (Grade ≥ 3) were observed at a higher incidence in the VELCADE containing treatment regimen as compared with a historical control study in which the backbone regimen was given alone: in Block 1 peripheral sensory neuropathy (3% versus 0%); ileus (2.1% versus 0%); hypoxia (8% versus 2%).
Danish: Følgende bivirkninger (grad ≥ 3) blev observeret med en hyppigere forekomst i behandlingsregimet med VELCADE sammenlignet med et historisk kontrolstudie, i hvilket baggrundsregimet blev givet alene: I blok 1 perifer sensorisk neuropati (3 % kontra 0 %), ileus (2,1 % kontra 0 %), hypoksi (8 % kontra 2 %).
English: The overall incidence of diarrhoea, gastrointestinal and abdominal pain, asthenic conditions, upper respiratory tract infections and peripheral neuropathies were 12%-15% lower in the subcutaneous group than in the intravenous group.
Danish: Den samlede forekomst af diarré, smerter i mave-tarm-kanalen og abdomen, asteniske tilstande, øvre luftvejsinfektioner og perifere neuropatier var 12 % til 15 % lavere i den subkutane gruppe end i den intravenøse gruppe.
English: In the VcR-CAP group, 22.5% of patients received platelet transfusions compared to 2.9% of patients in the R-CHOP group.
Danish: I VcR-CAP-gruppen fik 22,5 % af patienterne trombocyttransfusioner sammenlignet med 2,9 % af patienterne i R-CHOP-gruppen.
English: No new safety concerns were observed when VELCADE was added to the standard pediatric pre-B cell ALL chemotherapy backbone.
Danish: Der observeredes ikke nogen nye sikkerhedsproblemer, når VELCADE blev føjet til standard-kemoterapiregimet for pædiatrisk præ-B-celle ALL.
English: Complete blood counts (CBC) with differential and including platelet counts should be frequently monitored throughout treatment with VELCADE.
Danish: Komplet blodtælling (CBC) med differentialtælling og inklusive trombocyttal skal gennemføres hyppigt under behandlingen med VELCADE.
English: Grade ≥ 3 non-haematological toxicities considered to be related to VELCADE
Danish: Grad ≥ 3 ikke-hæmatologisk toksicitet, som anses for relateret til VELCADE
English: Table 15: Summary of efficacy analyses comparing subcutaneous and intravenous administrations of VELCADE
Danish: Tabel 15: Oversigt over effektanalyser til sammenligning af subkutan og intravenøs administration af VELCADE
English: The Reconstitution, dosing and administration booklet shall contain the following key elements:
Danish: Brochuren om rekonstitution, dosering og administration skal indeholde følgende hovedpunkter:
English: This study met its primary objective of non-inferiority for response rate (CR+PR) after 4 cycles of single agent VELCADE for both the subcutaneous and intravenous routes, 42% in both groups.
Danish: Studiet opfyldte det primære mål, som var non-inferiority, hvad angår responsrate (CR+PR) efter 4 cyklusser med VELCADE som monoterapi for såvel subkutan som intravenøs administration, 42 % i begge grupper.
English: Therefore, caution should be used during handling and preparation of VELCADE.
Danish: Der skal derfor udvises forsigtighed ved håndtering og anvendelse af VELCADE.
English: Table 9: Incidence of peripheral neuropathy during induction treatment by toxicity and treatment discontinuation due to peripheral neuropathy IFM-2005-01
Danish: Tabel 9: Forekomst af perifer neuropati under induktionsbehandling efter toksicitet og behandlingsseponering på grund af perifer neuropati IFM-2005-01
English: • Once dissolved, withdraw the appropriate amount of the reconstituted solution according to calculated dose based upon the patient´s Body Surface Area.
Danish: • Når det er opløst, udtrækkes den relevante mængde af den rekonstituerede opløsning i henhold til beregnet dosis ud fra patientens legemsoverflade.
English: Notable differences in the safety profile of VELCADE administered subcutaneously versus intravenously as single agent
Danish: Bemærkelsesværdige forskelle mellem sikkerhedsprofilen for VELCADE administreret subkutant versus intravenøst som monoterapi
English: A statistically significant benefit (p < 0.001) in favour of the VcR-CAP treatment group over the R-CHOP group was observed for TTP (median 30.5 versus 16.1 months), TNT (median 44.5 versus 24.8 months) and TFI (median 40.6 versus 20.5 months).
Danish: Der blev observeret en statistisk signifikant fordel (p < 0,001) for VcR-CAP-gruppen i forhold til R-CHOP-gruppen for TTP (median 30,5 kontra 16,1 måneder), TNT (median 44,5 kontra 24,8 måneder) og TFI (median 40,6 kontra 20,5 måneder).
English: • Partial or total loss of vision
Danish: • Delvist eller totalt synstab
English: The safety and efficacy of VELCADE in children below 18 years of age have not been established (see sections 5.1 and 5.2).
Danish: VELCADEs sikkerhed og virkning hos børn under 18 år er ikke klarlagt (se pkt.
English: VELCADE treatment is very commonly associated with haematological toxicities (thrombocytopenia, neutropenia and anaemia).
Danish: Behandlingen med VELCADE forbindes meget ofte med hæmatologisk toksicitet (trombocytopeni, neutropeni og anæmi).
English: The two treatment groups were similar with regard to the overall incidence of all-grade bleeding events (6.3% in the VcR-CAP group and 5.0% in the R-CHOP group) as well as Grade 3 and higher bleeding events (VcR-CAP: 4 patients [1.7%]; R-CHOP: 3 patients [1.2%]).
Danish: De to behandlingsgrupper var sammenlignelige, hvad angår den samlede forekomst af alle grader af blødningshændelser (6,3 % i VcR-CAP-gruppen og 5,0 % i R-CHOP-gruppen) såvel som blødningshændelser af grad 3 og højere (VcR-CAP: 4 patienter [1,7 %]; R-CHOP: 3 patienter [1,2 %]).
English: Table 1: Recommended* posology modifications for bortezomib-related neuropathy Severity of neuropathy
Danish: Tabel 1: Anbefalede* dosisændringer ved bortezomib-relateret neuropati Sværhedsgrad af perifer neuropati
English: Neuropathic pain and/or peripheral neuropathy
Danish: Neuropatiske smerter og/eller perifer neuropati
English: In a study in previously untreated mantle cell lymphoma patients, 42.9% and 10.4% of patients exposed to VELCADE were in the range 65-74 years and ≥ 75 years of age, respectively.
Danish: I et studie med patienter med tidligere ubehandlet mantle-celle-lymfom var henholdsvis 42,9 % og 10,4 % af de patienter, der fik VELCADE, i alderen 65-74 år og ≥ 75 år.
English: Limited information on VELCADE retreatment in relapsed multiple myeloma is available.
Danish: Der foreligger begrænsede oplysninger om VELCADE til genbehandling af recidiverende myelomatose.
English: • Inflammation or haemorrhage of the blood vessels that can appear as small red or purple dots
Danish: • Betændelse eller blødning i blodkarrene; det kan vise sig som små rødlige eller lilla prikker
English: Hazard ratio (95% CI) p-value
Danish: Hazard ratio (95 % CI) p-værdi
English: In vitro studies indicate that bortezomib is a weak inhibitor of the cytochrome P450 (CYP) isozymes 1A2, 2C9, 2C19, 2D6 and 3A4.
Danish: In vitro-studier viser, at bortezomib er en svag hæmmer af cytochrom P450 (CYP)-isozymer 1A2, 2C9, 2C19, 2D6 og 3A4.
English: Reduce VELCADE to 1.0 mg/m or
Danish: Reducer VELCADE til 1,0 mg/m eller
English: The median duration of complete response was 42.1 months in the VcR-CAP group compared with 18 months in the R-CHOP group.
Danish: Den mediane varighed af komplet respons var 42,1 måneder i VcR-CAP-gruppen sammenlignet med 18 måneder i R-CHOP-gruppen.
English: Following an intravenous bolus or subcutaneous injection of a 1.3 mg/m2 dose to patients with multiple myeloma (n=14 in the intravenous group, n=17 in the subcutaneous group), the total systemic exposure after repeat dose administration (AUClast) was equivalent for subcutaneous and intravenous administrations.
Danish: Efter en intravenøs bolus- eller subkutan injektion af en dosis på 1,3 mg/m2 hos patienter med myelomatose (n = 14 i den intravenøse gruppe, n = 17 i den subkutane gruppe) sås samme totale systemiske eksponering efter gentagne doser (AUClast) for subkutan og intravenøs administration.
English: Vc=VELCADE; Dex=dexamethasone CR=Complete Response; nCR=near Complete response PR=Partial Response; MR=Minimal response
Danish: Vc = VELCADE; Dex = dexamethason CR = fuldstændigt respons; nCR = næsten fuldstændigt respons PR = partielt respons; MR = minimalt respons
English: This interim analysis showed a TTP risk reduction of 45% (95% CI; 29-57%, p < 0.0001) for patients treated with combination therapy of VELCADE and pegylated liposomal doxorubicin.
Danish: Denne interimanalyse viste en TTP-risikoreduktion på 45 % (95 % CI, 29-57 %, p < 0,0001) for patienter behandlet med kombinationsbehandlingen VELCADE og pegyleret liposomal doxorubicin.
English: Developmental toxicity studies in the rat and rabbit have shown embryo-fetal lethality at maternally toxic doses, but no direct embryo-foetal toxicity below maternally toxic doses.
Danish: Udviklingstoksicitetsstudier på rotter og kaniner har vist embryo/fosterdødelighed ved maternelt toksiske doser, men ingen direkte embryo/fostertoksicitet ved ikke maternelt toksiske doser.
English: Caution should be exercised when bortezomib is combined with CYP3A4- or CYP2C19 substrates (see section 4.5).
Danish: Der skal udvises forsigtighed, når bortezomib kombineres med CYP3A4- eller CYP2C19substrater (se pkt.
English: Table 13: Efficacy results from study MMY-3010
Danish: Tabel 13: Effektresultater fra studie MMY-3010
English: • to remind that patients receiving VELCADE in combination with thalidomide should adhere to the pregnancy prevention programme of thalidomide, with reference to the SmPC of thalidomide for additional information.
Danish: • for at minde patienter, der modtager VELCADE sammen med thalidomid, om, at de skal overholde det svangerskabsforebyggende program for thalidomid, og med reference til produktresuméet for thalidomid for yderligere oplysninger.
English: Dose adjustments during treatment for patients with previously untreated mantle cell lymphoma Prior to initiating a new cycle of therapy:
Danish: Dosisjustering under behandlingen af patienter med tidligere ubehandlet mantle-celle-lymfom Før påbegyndelse af en ny behandlingscyklus:
English: In particular, tell your doctor if you are using medicines containing any of the following active substances: - ketoconazole, used to treat fungal infections ritonavir, used to treat HIV infection - rifampicin, an antibiotic used to treat bacterial infections - carbamazepine, phenytoin or phenobarbital used to treat epilepsy - St. John's Wort (Hypericum perforatum), used for depression or other conditions - oral antidiabetics
Danish: Særligt skal du fortælle lægen, hvis du bruger medicin, som indeholder følgende aktive stoffer: - ketoconazol, som bruges til behandling af svampeinfektioner - ritonavir, bruges til behandling af Hiv-infektion - rifampicin, et antibiotikum, som bruges til at behandle bakterie-infektioner - carbamazepin, phenytoin eller phenobarbital til behandling af epilepsi - perikon (Hypericum perforatum), naturmedicin som bruges mod depression eller andre lidelser - tabletter til behandling af sukkersyge (diabetes)
English: • a dose-calculation tool that enables prescribers to input a patient's height and weight in order to calculate the body surface area (BSA) and thereby to determine the appropriate VELCADE dose.
Danish: • et redskab til beregning af dosis, hvor den ordinerende læge kan indlæse patientens højde og vægt for ud fra disse at beregne arealet af legemsoverfladen og derved fastsætte en passende dosering af VELCADE.
English: A pharmacokinetic study was conducted in patients with various degrees of renal impairment who were classified according to their creatinine clearance values (CrCL) into the following groups: Normal (CrCL ≥ 60 ml/min/1.73 m2, n=12), Mild (CrCL=40-59 ml/min/1.73 m2, n=10), Moderate
Danish: Et farmakokinetisk studie er foretaget hos patienter med varierende grad af nedsat nyrefunktion, som blev klassificeret i følgende grupper i henhold til deres kreatininclearance (CrCl): Normal (CrCl ≥ 60 ml/min/1,73 m2, n = 12), Mild (CrCl = 40-59 ml/min/1,73 m2, n = 10), Moderat
English: Include all CR+CRu, by IRC, bone marrow and LDH.
Danish: Inkluderer alle CR + CRu, efter IRC, knoglemarv og LDH.
English: VELCADE therapy should be withheld
Danish: VELCADE-behandling skal tilbageholdes
English: Caution is advised when treating patients with a history of syncope receiving medicinal products known to be associated with hypotension; or who are dehydrated due to recurrent diarrhoea or vomiting.
Danish: Der skal udvises forsigtighed, ved behandling af patienter med tidligere synkope, der får lægemidler som er kendt for at være forbundet med hypotension, eller patienter som er dehydreret pga. tilbagevendende diaré eller opkastning.
English: • Inject the solution as a 3-5 second bolus intravenous injection through a peripheral or central intravenous catheter into a vein.
Danish: • Sprøjt opløsningen som en 3-5 sek. intravenøs bolusinjektion gennem et perifert eller centralt intravenøst kateter ind i en vene.
English: VELCADE therapy should be withheld until symptoms of the toxicity have resolved to Grade 2 or better.
Danish: VELCADE-behandlingen skal indstilles, indtil symptomerne på toksicitet er bedret til grad 2 eller bedre.
English: Six VELCADE cycles are recommended, although for patients with a response first documented at cycle 6, two additional VELCADE cycles may be given.
Danish: Seks VELCADE-cyklusser anbefales, men patienter med et respons, som først dokumenteres ved cyklus 6, kan gives yderligere to VELCADE-cyklusser.
English: Progressive multiple myeloma
Danish: Progressiv myelomatose
English: The primary efficacy endpoint was TTP while the secondary efficacy endpoints were OS and ORR (CR+PR), using the European Group for Blood and Marrow Transplantation (EBMT) criteria.
Danish: Det primære effektendepunkt var TTP, og det sekundære effektendepunkt var OS og ORR (CR+PR), hvor kriterierne fra The European Group for Blood and Marrow Transplantation (EBMT) blev brugt.
English: Table 10: Incidence of peripheral neuropathy in study LYM-3002 by toxicity and treatment discontinuation due to peripheral neuropathy VcR-CAP (N=240)
Danish: Tabel 10: Forekomst af perifer neuropati i studie LYM-3002 efter toksicitet og behandlingsseponering som følge af perifer neuropati VcR-CAP (N = 240)
English: Log rank test adjusted for stratification factors: ISS staging and number of prior lines.
Danish: Logrank-test justeret for stratifikationsfaktorer: ISS-score og antal tidligere linjer.
English: Dexamethasone was administered in combination with VELCADE to 83 patients in Cycle 1 with an additional 11 patients receiving dexamethasone during the course of VELCADE retreatment cycles.
Danish: Dexamethason blev administreret i kombination med VELCADE til 83 patienter i cyklus 1, mens yderligere 11 patienter fik dexamethason i løbet af efterfølgende VELCADE behandlingscyklusser.
English: Median OS was 90.7 months for the VcR-CAP group compared with 55.7 months for the R-CHOP group (HR=0.66; p=0.001).
Danish: Den mediane OS var 90,7 måneder for VcR-CAP-gruppen sammenlignet med 55,7 måneder for R-CHOP-gruppen (HR = 0,66; p = 0,001).
English: VELCADE 3.5 mg reconstituted solution is administered subcutaneously through the thighs (right or left) or abdomen (right or left).
Danish: VELCADE 3,5 mg rekonstitueret opløsning indgives subkutant i låret (højre eller venstre) eller abdomen (højre eller venstre side).
English: VIAL VELCADE 3.5 mg FLAG LABEL
Danish: HÆTTEGLAS VELCADE 3,5 mg FLAG-LABEL
English: Change VELCADE treatment schedule to 1.3 mg/m2 once per week
Danish: Skift behandlingsplanen for VELCADE til 1,3 mg/m2 en gang om ugen
English: p-value from the Cochran Mantel-Haenszel chi-square test adjusted for the stratification factors; analysis by line of therapy excludes stratification for therapeutic history
Danish: p-værdi fra Cochran-Mantel-Haenszel chi-square-testen justeret for stratifikationsfaktorer; analyse ud fra behandling udelukker opdeling på tidligere behandling
English: Patients had IgG/IgA/Light chain myeloma in 63%/25%/8% instances, a median hemoglobin of 105 g/l, and a median platelet count of 221.5 x 10
Danish: Patienterne havde IgG/IgA/lette kæder af myelomer i henholdsvis 63 %/25 %/8 % tilfælde, mediant hæmoglobin på 105 g/l og mediant trombocyttal på 221,5 x 10
English: In the Phase III study in patients with previously untreated multiple myeloma, the overall incidence of herpes zoster reactivation was more common in patients treated with VELCADE+Melphalan+Prednisone compared with Melphalan+Prednisone (14% versus 4% respectively).
Danish: I fase III-studiet med hidtil ubehandlede myelomatosepatienter var den samlede forekomst af herpes zoster-reaktivering større hos patienter behandlet med VELCADE+melphalan+prednison sammenlignet med melphalan+prednison (14 % versus 4 %).
English: Progression free survival (IRC) Events n (%)
Danish: Progressionsfri overlevelse (IRC) Hændelser n (%)
English: • Induction Transplant Regimens Graph.
Danish: • Graf over induktionstransplantationsregimer.
English: Uncommon Erythema multiforme, Urticaria, Acute febrile neutrophilic dermatosis, Toxic skin eruption, Toxic epidermal necrolysis Stevens-Johnson syndrome
Danish: Erythema multiforme, urticaria, akut febril neutrofil dermatose, toksisk huderuption, toksisk epidermal nekrolyse Stevens-Johnsons syndrom
English: Unopened vial 3 years
Danish: Hætteglas inden anbrud 3 år
English: Melphalan and prednisone should both be given orally on days 1, 2, 3 and 4 of the first week of each VELCADE treatment cycle.
Danish: Melphalan og prednison bør begge gives oralt på dag 1, 2, 3 og 4 i den første uge af hver behandlingscyklus med VELCADE.
English: Based on the limited contribution (7%) of CYP2D6 to the metabolism of bortezomib, the CYP2D6 poor metaboliser phenotype is not expected to affect the overall disposition of bortezomib.
Danish: På baggrund af det begrænsede bidrag (7 %) fra CYP2D6 til metaboliseringen af bortezomib, forventes det ikke, at CYP2D6-fænotypen som metaboliserer dårligt, påvirker den samlede disponering for bortezomib.
English: • Difficulty or problems in sleeping, sweating, anxiety, mood swings, depressed mood,
Danish: • Besvær eller problemer med at sove, svedeture eller angst, humørsvingninger, nedsat humør,
English: • Yellow discolouration of eyes and skin (jaundice)
Danish: • Gulfarvning af øjne og hud (gulsot)
English: Fertility Fertility studies were not conducted with VELCADE (see section 5.3).
Danish: Fertilitet Der er ikke udført fertilitetsstudier med VELCADE (se pkt.
English: One hundred and thirty patients (≥ 18 years of age) with multiple myeloma who previously had at least partial response on a VELCADE-containing regimen were retreated upon progression.
Danish: 130 patienter (≥ 18 år) med myelomatose, som tidligere havde haft mindst partielt respons på et VELCADE holdigt regime, fik ny behandling ved progression.
English: For VELCADE-related neuropathic pain and/or peripheral neuropathy, hold and/or modify VELCADE as outlined in Table 1.
Danish: I tilfælde af VELCADE-relateret neuropatisk smerte og/eller perifer neuropati indstilles og/eller modificeres VELCADE-behandlingen som beskrevet i tabel 1.
English: The pharmacokinetics of bortezomib were characterized following twice weekly intravenous bolus administration of 1.3 mg/m2 doses to 104 pediatric patients (2-16 years old) with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).
Danish: Alder Bortezomibs farmakokinetik blev karakteriseret efter intravenøs bolus-administration af 1,3 mg/m2 to gange om ugen hos 104 pædiatriske patienter (2-16 år) med akut lymfoblastær leukæmi (ALL) eller akut myeloid leukæmi (AML).
English: • symptoms of tumor lysis syndrome such as muscle cramping, muscle weakness, confusion,
Danish: • symptomer på tumorlysesyndrom, som f.eks. muskelkramper, muskelsvaghed, forvirring,
English: Main efficacy results are presented in Table 13.
Danish: De væsentligste effektresultater er præsenteret i Tabel 13.
English: A Phase II, single-arm activity, safety, and pharmacokinetic trial conducted by the Children's Oncology Group assessed the activity of the addition of bortezomib to multi-agent re-induction chemotherapy in paediatric and young adult patients with lymphoid malignancies (pre-B cell acute lymphoblastic leukemia [ALL], T-cell ALL, and T-cell lymphoblastic lymphoma [LL]).
Danish: Et fase II-forsøg med en enkelt arm vedrørende aktivitet, sikkerhed og farmakokinetik udført af Children's Oncology Group vurderede virkningen af at tilføje bortezomib til reinduktionskemoterapi med flere stoffer hos pædiatriske og unge voksne patienter med lymfoid malignitet (akut præ-B-celle lymfoblastær leukæmi [ALL], T-celle ALL og T-celle lymfoblastært lymfom [LL]).
English: 1-year Overall Survival (%) (95% CI)
Danish: Samlet overlevelse efter 1 år (%) (95 % CI)
English: Data from in vitro, ex-vivo, and animal models with bortezomib suggest that it increases osteoblast differentiation and activity and inhibits osteoclast function.
Danish: Resultater fra in vitro-, ex-vivo- og dyremodelforsøg med bortezomib tyder på, at bortezomib øger osteoblastdifferentieringen og -aktiviteten samt hæmmer osteoklastfunktionen.